LRMR

3.1402.48%
JT

Joseph Truitt

Independent Chairman of the Board

Mr. Joseph Truitt, also known as Joe, is Independent Director of Century Therapeutics, Inc. from September 9, 2026. He is CEO & Director of iECURE, Inc. He is Business Advisors & Strategic Alliances of Vesselon Inc He serves as CEO & Director at iECURE. He has been Chairman of the Board at Larimar Therapeutics, Inc., since May 28, 2020. He served as Chief Executive Officer at BioSpecifics Technologies Corp. since May 7, 2020 through December 2020. Mr. Truitt had been Interim Chief Executive Officer at BioSpecifics Technologies Corp. since April 2020 until May 7, 2020. Mr. Truitt served as Director at BioSpecifics Technologies Corp. since April 2020. Mr. Truitti was the Chief Executive Officer at Achillion Pharmaceuticals, Inc. from May 1, 2018 to April 2020. Mr. Truitt serves as the Chief Executive Officer of Iecure Inc., a gene editing company and is on the Board of CodeBio, a gene therapy development company. Mr. Truitti was President at Achillion Pharmaceuticals, Inc. since February 2018 until to April 2020. He served as its Chief Commercial Officer and an Executive Vice President of Business Development from January 2009 to September 11, 2017 and from March 06, 2014 to September 11, 2017 respectively. Mr. Truitt joined Achillion from Viropharma, Inc. following its acquisition of Lev Pharmaceuticals. At Lev, Mr. Truitt was most recently Vice President of Business Development and Product Strategy and led the build out of the commercial team and infrastructure in preparation for product launch. Mr. Truitt served as Senior Vice President of Business Development at Achillion Pharmaceuticals, Inc. from February 03, 2010 to March 06, 2014 and its Chief Operating Officer since September 11, 2017 until May 2, 2018. Mr. Truitti served as Business Consultant of CD Diagnostics, LLC. (AKA CD Diagnostics, Inc.). He served as Vice President of Business Development at Achillion Pharmaceuticals, Inc. since January 2009 and served as its Vice President until February 03, 2012. He served as Vice President of Business Development & Product Strategy at Lev Pharmaceuticals Inc. since November 2007. He served as Vice President of Sales and Marketing at Lev Pharmaceuticals Inc. from August 2006 to November 2007. He was responsible for building the sales, marketing and reimbursement team in anticipation of the launch of Lev Pharmaceuticals Inc.'s lead product candidate, C1-inhibitor for the treatment of hereditary angioedema ('HAE'), in Phase III clinical trials. At Johnson & Johnson, he served as Vice President of Sales and Operations and directed OraPharma's commercial operations and had P&L responsibility for sales, operations and national accounts. He built the sales management team at OraPharma Inc. and led the successful launch of OraPharma Inc.'s flagship product, Arestin(R). He spent nine years at TAP Pharmaceuticals Inc. in a variety of sales and marketing roles before a two-year role as a consultant at IMS Health. He had been Director of Achillion Pharmaceuticals, Inc. since May 2, 2018 until January 28, 2020. Mr. Truitt previously was a Captain in the United States Marine Corps. Mr. Truitt has a BS degree in Marketing from LaSalle University and an MBA degree from St. Joseph's University Haub School of Business.

Positions